The Life Sciences team advised Cadent Therapeutics as it closed a $40 million Series B financing round to advance its pipeline of novel therapies for movement and cognitive disorders. The financing was led by Cowen Healthcare Investments and Atlas Venture, with participation from Qiming Venture Partners, Access Industries, Clal Biotechnology Industries and Novartis Institutes for Biomedical Research.
In addition, Cadent has entered into an exclusive license and collaboration agreement with Novartis to develop a medicine that modulates NMDA receptors for the treatment of people with treatment resistant depression.
Cadent Therapeutics is creating breakthrough therapies for the treatment of movement disorders and cognitive impairment. The company combines target specificity, patient selection, drug design and optimization, and novel quantitative endpoints to create first-in-class molecules to treat movement and cognitive disorders.
For additional details on the financing, please read the press release.